Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Financings Of The Fortnight: Secondary Offerings Up From Pace Set In 2010 And 2011

Jul 13 2012

• By Alex Lash, Maureen Riordan, and John Davis

Related Content

GenKyoTex, PsiOxus Raise VC Funding In Europe To Reach Phase II POC

Jul 09 2012

PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings

Jul 05 2012

Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition

Dec 29 2011

$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

Jun 30 2012

Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own

Sep 19 2011

Related Companies

Human Genome Sciences, Inc.

Vertex Pharmaceuticals Incorporated

Dendreon Corporation

Synageva BioPharma Corp.

ImmunoGen, Inc.

Alexion Pharmaceuticals Inc.

BioMarin Pharmaceutical Inc.

Enobia Pharma Inc.

GenKyoTex S.A.

Sagimet Biosciences

Synageva BioPharma Corp.

Roche Holding AG

Bristol Myers Squibb Company

Nektar Therapeutics

UCB S.A.

Pfizer Inc.

Vivoryon Therapeutics N.V.

Novagali Pharma SA

Regado Biosciences, Inc.

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window